%0 Journal Article %A Alfredo Maria Gravagnuolo %A Layla Faqih %A Cara Cronshaw %A Jackie Wynn %A Lewis Burglin %A Paul Klapper %A Mark Wigglesworth %T Epidemiological Investigation of New SARS-CoV-2 Variant of Concern 202012/01 in England %D 2021 %R 10.1101/2021.01.14.21249386 %J medRxiv %P 2021.01.14.21249386 %X Lighthouse Labs network tests for the presence of RNA of SARS-CoV-2, the causative agent of COVID-19. The Thermofisher TaqPath assay targets three regions of SARS-CoV-2; ORF1ab, N and S-genes. The assay identified a drop in S-gene target detection among positive samples due to the circulation of a new SARS-CoV-2 Variant of Concern (VOC) designated as 202012/01. By end of December 2020, 60% of daily positive test results at Alderley Park Lighthouse Labs, were linked to the new Variant of Concern. This timeline view identifies the rapid spread of the variant across the country.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOVID-19 National Testing Programme - Department of Health & Social CareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The manuscript was reviewed by the Head of Approvals Support, NHS Health Research Authority (HRA-NHS, UK), who confirmed that the study which used unlinked and anonymised data was health surveillance and did not require NHS Research ethics review (letter available upon request)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull data available upon formal request addressed to the corresponding author Layla Faqih for auditing purposes https://lighthouselabsalderleypark.org.uk/ %U https://www.medrxiv.org/content/medrxiv/early/2021/01/15/2021.01.14.21249386.full.pdf